Hormonal contraceptive choice for women with PCOS: A systematic review of randomized trials and observational studies
It is an agonist at the trace amine-associated receptor (TAAR1), stimulating the release of both norepinephrine and epinephrine
This may help reduce oxidative stress and support healthier skin cells
Semaglutide users in the STEP 1 trial lost an average of 14.9% of their body weight over 68 weeks
Key safety monitoring parameters include: Baseline and periodic assessment of nutritional status (complete blood count, comprehensive metabolic panel, vitamin levels, albumin) Renal function monitoring, particularly during dose escalation, due to risk of acute kidney injury from dehydration Evaluation for gastrointestinal symptoms and differentiation from surgical complications Monitoring for gallbladder disease, which may be increased with weight loss and semaglutide use Assessment of medication adherence and injection technique Eye examination in patients with diabetes due to potential risk of diabetic retinopathy progression with rapid glycemic improvement Regular follow-up with both bariatric surgery and endocrinology or obesity medicine teams when possible Patients should be counseled to report severe or persistent nausea, vomiting, abdominal pain, or inability to maintain adequate hydration or nutrition, as these may warrant dose adjustment, temporary discontinuation, or further evaluation for surgical complications
